Comparative Pharmacology
Head-to-head clinical analysis: EFFEXOR XR versus MILNACIPRAN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFFEXOR XR versus MILNACIPRAN HYDROCHLORIDE.
EFFEXOR XR vs MILNACIPRAN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It potently inhibits the reuptake of serotonin and norepinephrine, and weakly inhibits dopamine reuptake. It has no significant affinity for muscarinic, histaminergic, or alpha1-adrenergic receptors.
Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) with approximately 3-fold higher potency for norepinephrine reuptake inhibition compared to serotonin. It does not significantly affect dopamine or other neurotransmitter reuptake.
75 mg orally once daily; may increase by 75 mg/day increments every 4-7 days to max 225 mg/day.
50 mg orally twice daily with food, increased to 100 mg twice daily based on tolerability and efficacy.
None Documented
None Documented
Venlafaxine: 3-7 hours (short, requires extended-release formulation for once-daily dosing); active metabolite O-desmethylvenlafaxine: 9-13 hours (contributes to overall clinical effect). Steady-state achieved within 3 days.
Terminal elimination half-life is approximately 6-8 hours in young adults; prolonged to 10-15 hours in elderly or patients with renal impairment (CrCl <30 mL/min).
Renal: approximately 87% as metabolites (including venlafaxine, O-desmethylvenlafaxine, and other minor metabolites) and ≤5% as unchanged drug. Biliary/fecal: minimal (about 2%).
Primarily renal: ~60% excreted unchanged in urine; ~23% as glucuronide conjugates; ~3% as other metabolites; biliary/fecal excretion accounts for <5%.
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant